State-of-the-art of multidisciplinary approach of bone metastasis-directed therapy: review and challenging questions for preparation of a GEMO practice guidelines
- PMID: 40220136
- PMCID: PMC11993453
- DOI: 10.1007/s10555-025-10262-6
State-of-the-art of multidisciplinary approach of bone metastasis-directed therapy: review and challenging questions for preparation of a GEMO practice guidelines
Abstract
Bone is a common secondary site of dissemination during the course of cancer. Bone metastases (BM) can be associated with skeletal-related events (SRE) such as disabling pain, hypercalcemia, and bone instability that leads to pathological fractures or spinal cord compression. SRE contribute to high morbidity as well as, mortality, and have a negative economic impact. Modern management of BM integrates focal treatments (such as radiotherapy, surgery, and interventional radiology), orthoses, and antiresorptive and systemic oncological treatment. The choice of a metastasis-directed therapy depends on the objective of the treatment, the patient characteristics, and the complete assessment of the bone lesion (pain, neurological risk, and instability). In the narrative review present herein, we aim to provide an updated summary of the literature, with description of the advantages and disadvantages of current and emerging strategies in the multimodal treatment of BM and, based on these data, an updated algorithm for the management of BM.
Keywords: Bone metastases; Interventional radiology; Radiotherapy; Skeletal-related event; Surgery.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing Interests: Competing Interests
Figures



Similar articles
-
Bisphosphonates for breast cancer.Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. PMID: 16034900 Updated.
-
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.Cochrane Database Syst Rev. 2020 Dec 3;12(12):CD013020. doi: 10.1002/14651858.CD013020.pub2. Cochrane Database Syst Rev. 2020. PMID: 33270906 Free PMC article.
-
Bisphosphonates and other bone agents for breast cancer.Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4. Cochrane Database Syst Rev. 2017. PMID: 29082518 Free PMC article.
-
Bisphosphonates for breast cancer.Cochrane Database Syst Rev. 2002;(1):CD003474. doi: 10.1002/14651858.CD003474. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. PMID: 11869664 Updated.
-
A systematic overview of radiation therapy effects in skeletal metastases.Acta Oncol. 2003;42(5-6):620-33. doi: 10.1080/02841860310014895. Acta Oncol. 2003. PMID: 14596519
References
-
- Ryan, C., Stoltzfus, K. C., Horn, S., Chen, H., Louie, A. V., Lehrer, E. J., et al. (2022). Epidemiology of bone metastases. Bone,158, 115783. 10.1016/j.bone.2020.115783 - PubMed
-
- Van den Brande, R., Cornips, E. M., Peeters, M., Ost, P., Billiet, C., & Van de Kelft, E. (2022). Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review. Journal Bone Oncology,35, 100446. 10.1016/j.jbo.2022.100446 - PMC - PubMed
-
- Decroisette, C., Monnet, I., Berard, H., Quere, G., Le Caer, H., Bota, S., et al. (2011). Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (GFPC 0601). Journal Thoracic Oncology Office Publication International Association Study Lung Cancer,6, 576–582. 10.1097/JTO.0b013e318206a1e3 - PubMed
-
- Barzilai, O., Laufer, I., Yamada, Y., Higginson, D. S., Schmitt, A. M., Lis, E., et al. (2017). Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: Neurologic, oncologic, mechanicals stability, and systemic disease. Journal Clinical Oncology Office Journal American Society Clinical Oncology,35, 2419–2427. 10.1200/JCO.2017.72.7362 - PubMed
-
- Zamani-Siahkali, N., Mirshahvalad, S. A., Farbod, A., Divband, G., Pirich, C., Veit-Haibach, P., et al. (2024). SPECT/CT, PET/CT, and PET/MRI for response assessment of bone metastases. Seminars in Nuclear Medicine,S0001–2998(23), 00093–00094. 10.1053/j.semnuclmed.2023.11.005 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical